All News #Library
Biotech
Spyglass Pharma Reports Successful 12-Month Phase 1/2 Trial
09 Mar 2026 //
GLOBENEWSWIRE
Eleva Initiates Phase 1B Trial For CPV-104 In C3G, Patients
21 Oct 2025 //
GLOBENEWSWIRE
Eleva Gives 1st Factor H biological Dose in C3-Glomerulopathy
07 Jul 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support